source
- uniQure shares tumble 41% after Huntington’s gene therapy misses primary endpointuniQure reported updated 48‑month data from its phase 1/2 trial of AMT‑130 in Huntington’s disease. The therapy showed a 44% slowing of disease progression on the composite Unified Huntington’s Dis…
- Regulators Discuss Plans to Streamline Europe’s Drug Approval Process at 2026 RAPS ConvergenceA panel of European regulators gathered at the 2026 RAPS Convergence in Charlotte, North Carolina to discuss ongoing initiatives aimed at simplifying the continent’s regulatory framework. The offi…